Progenity Inc. (NASDAQ: PROG) has announced a new patent associated with a single-molecule detection platform currently under development.
The patent covers single target nucleic acid molecules
The US Patent and Trademark Office issued the company with Patent No. 11, 186,863 entitled, “Methods, Systems and Composition for counting Nucleic Acid Molecules.” The Issued patent claims cover methods for capturing, amplifying, and imaging single target nucleic acid molecule copies.
General Manager, Diagnostics Matthew Cooper, said, “This patent covers critical methods for counting target molecules, obviating the need for sequencing. Our Single-Molecule Detection Platform is designed to enable tests such as noninvasive prenatal testing (NIPT) or liquid biopsy for cancer to be performed without the need for costly, complex sequencing, which would greatly reduce cost and simplify operational implementation. The platform also has potential applications beyond nucleic acids, such as proteins. As Progenity migrates away from the commercial diagnostics business, we are actively seeking partners to further develop this promising asset.”
Progenity has built a strong patent portfolio to support its single-molecule detection platform, which includes six patent families covering various aspects of its molecular counting platform and a different family dedicated to detecting nucleosomal positioning patterns, which can be vital for determining cell-free DNA tissue-of-origin. These patents are part of Progenity’s corporate portfolio, including 96 patent families with 180 issued patents and over 220 patent applications. The portfolio comprises applications and patents for medication administration methods and devices, GI sampling and diagnostics methods and devices, illness treatment methods and compositions, and molecular and protein tools, assays, and diagnostics.
Progenity focuses on women health
The company is a biotech firm that focuses on gastrointestinal health, women’s health, and oral biotherapeutics, among other areas. In addition, its molecular testing tools and the development of a portfolio of investigational ingestible devices meant to provide precise diagnostic samples and medication delivery solutions using a multi-omics approach, combining genomes, proteomics, epigenomics, and metabolomics. Progenity’s mission is to make healthcare more precise and personalized by enhancing illness diagnosis and patient outcomes through localized treatment using targeted treatments.
